Asset Details
Do you wish to reserve the book?
Synthesis and Anti-Liver Fibrosis Research of Aspartic Acid Derivatives
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Synthesis and Anti-Liver Fibrosis Research of Aspartic Acid Derivatives
Do you wish to request the book?
Synthesis and Anti-Liver Fibrosis Research of Aspartic Acid Derivatives
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Synthesis and Anti-Liver Fibrosis Research of Aspartic Acid Derivatives
2024
Overview
Liver fibrosis plays an important role in the progression of liver disease, but there is a severe shortage of direct and efficacious pharmaceutical clinical interventions. Literature research indicates that aspartic acid exhibits hepatoprotective properties. In this paper, 32 target compounds were designed and synthesized utilizing aspartic acid as the lead compound, of which 22 were new compounds not reported in the literature. These compounds were screened for their inhibitory effects on the COL1A1 promoter to assess in vitro anti-liver fibrosis activity and summarized structure–activity relationships. Four compounds exhibited superior potency with inhibition rates ranging from 66.72% to 97.44%, substantially higher than EGCG (36.46 ± 4.64%) and L-Asp (11.33 ± 0.35%). In an LPS-induced inflammation model of LX-2 cells, both 41 and 8a could inhibit the activation of LX-2 cells, reducing the expression of COL1A1, fibronectin, and α-SMA. Upon further investigation, 41 and 8a ameliorated liver fibrosis by inhibiting the IKKβ-NF-κB signaling pathway to alleviate inflammatory response. Overall, the study evaluated the anti-liver fibrosis effects of aspartic acid derivatives, identified the potency of 41, and conducted a preliminary exploration of mechanisms, laying the foundation for the discovery of novel anti-liver fibrosis agents.
Publisher
MDPI AG,MDPI
Subject
/ Aspartic Acid - analogs & derivatives
/ Aspartic Acid - pharmacology
/ Catechin
/ Collagen Type I - metabolism
/ Collagen Type I, alpha 1 Chain - genetics
/ Fibrosis
/ Hepatic Stellate Cells - drug effects
/ Hepatic Stellate Cells - metabolism
/ Humans
/ IKKβ-NF-κB signaling pathway
/ Iodine
/ Kinases
/ Liver
/ Liver Cirrhosis - drug therapy
/ Liver Cirrhosis - metabolism
